What is L-HES (Lymphocytic Variant Hypereosinophilic Syndrome)?
L-HES is a rare disorder where abnormal clonal T-cells produce excessive amounts of cytokines (IL-4, IL-5, IL-13) that drive reactive eosinophil expansion, leading to elevated eosinophil counts and potential organ damage. 1
Key Characteristics
Disease Mechanism:
- L-HES represents a hybrid condition: it combines a clonal T-cell disorder with secondary (reactive) hypereosinophilia 1
- The abnormal T-cells have aberrant immunophenotypes and overproduce Th2 cytokines that stimulate eosinophil production 1
- The eosinophils themselves are NOT clonal—they are reactive to the cytokines produced by the abnormal T-cells 1
What Abnormal T-Cell Results Mean
Classic Immunophenotype Patterns: Your abnormal T-cell results likely show one of these patterns:
- Most common (73.6% of cases): CD3-negative, CD4-positive (CD3-CD4+) T-cells 1, 2
- Alternative patterns: Double-negative T-cells (CD3+, CD4-, CD8-) or cells lacking CD7 (CD3+, CD4+, CD7-) 1
Additional Diagnostic Features:
- Enhanced expression of CD2, CD5, CD45RO, and CD95 on these aberrant cells 3
- CCR8 is a dominant surface marker that helps identify these cells 4
- Elevated serum TARC (thymus and activation-related chemokine) levels, often >3000 pg/mL 3
- Elevated IgE levels (though not always present) 1
- Clonal T-cell receptor (TCR) gene rearrangement detected in 71-76% of cases 5, 6
Important caveat: A clonal TCR gene rearrangement alone is NOT sufficient to diagnose L-HES, as this can be nonspecific 1
Clinical Presentation
Most Common Manifestations:
- Skin involvement (81%): rashes, angioedema, urticaria, eczema 5, 2
- Lymphadenopathy (62%) 5
- Musculoskeletal (29%): including fasciitis 5, 7
- Gastrointestinal (24%) 5
- Pulmonary (19%) 5
- Cardiovascular (11.5%): less common than other HES subtypes but carries higher risk of lymphoma transformation 2
Critical Prognostic Information
Risk of Malignant Transformation:
- 10-20% of L-HES cases evolve to T-cell lymphoma or Sézary syndrome 1
- This typically occurs years after initial diagnosis (median 6-8 years) 5
- Risk factors for transformation include cardiovascular involvement and certain treatment exposures 2
- 10-year overall survival is 81.6%, but this underscores the need for long-term monitoring 2
Treatment Approach
First-Line Therapy:
- Corticosteroids are ALWAYS effective initially and should be the first-line treatment 5, 8
- All patients in published series achieved remission with corticosteroids 5
Reality of Long-Term Management:
- Most patients (approximately two-thirds) require corticosteroid-sparing agents due to steroid dependence 5, 7
- Interferon-alpha shows the best efficacy (8/8 responders in one series), but tolerance is poor and secondary resistance develops 7
- Anti-IL-5 antibodies (mepolizumab, benralizumab) effectively reduce eosinophil counts but have disappointing clinical responses in many cases 7, 8
- This suggests the aberrant T-cells themselves, not just the eosinophils, contribute directly to disease pathogenesis 4
Treatment-Refractory Disease:
- Approximately one-third of patients have mild disease not requiring maintenance therapy 7
- One-third have moderate disease manageable with standard therapies 7
- One-third have severe, treatment-refractory disease with significant morbidity and mortality 7
Essential Monitoring
Surveillance Requirements:
- Serial flow cytometry to track aberrant T-cell populations 6
- Regular assessment for lymphoma development (clinical exam, imaging as indicated)
- Organ function monitoring, particularly cardiac evaluation given endomyocardial involvement risk
- Serum TARC levels can help monitor disease activity 3
Critical distinction: Unlike FIP1L1-PDGFRA-positive chronic eosinophilic leukemia (which responds dramatically to imatinib), L-HES does NOT respond to tyrosine kinase inhibitors 5. In fact, imatinib use has been associated with increased risk of lymphoma transformation 2.